Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Introduction To Survival Analysis01:18

Introduction To Survival Analysis

Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time until a...
Actuarial Approach01:20

Actuarial Approach

The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal for immunotherapy of cancer·2026
Same author

Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival.

Cancer discovery·2026
Same author

Diagnostic delay in histiocytic neoplasms and its association with local resource deprivation.

Haematologica·2026
Same author

Enhanced Telehealth in Prostate Cancer.

JAMA network open·2026
Same author

Propensity Score-Matched External Controls in Rare Disease Trials: A Promising Tool Requiring Rigorous Validation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact.

Cancer·2026
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
Same journal

Maintenance therapy in gynecologic malignancies: Current and future state.

Cancer·2026
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Dynamic prognostication using conditional survival estimates.

Emily C Zabor1, Mithat Gonen, Paul B Chapman

  • 1Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York.

Cancer
|August 6, 2013
PubMed
Summary
This summary is machine-generated.

Conditional survival estimates offer a more relevant prognosis for cancer patients over time. This study shows traditional survival estimates underestimate long-term outlooks for stage III melanoma patients, highlighting the need for updated methods.

Keywords:
conditional survivalmelanomapatient counselingprognosissurvivorship

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Related Experiment Videos

Last Updated: May 9, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Area of Science:

  • Oncology
  • Biostatistics

Background:

  • Prognostic estimates are typically calculated from the time of diagnosis.
  • These estimates lose relevance as time from diagnosis increases.
  • Conditional survival provides a more accurate, time-dependent prognosis.

Purpose of the Study:

  • To evaluate the utility of conditional survival estimates in stage III melanoma.
  • To demonstrate how traditional survival estimates underestimate long-term survival.
  • To advocate for the routine use of conditional survival in clinical practice.

Main Methods:

  • Analysis of survival data from patients with stage III melanoma.
  • Comparison of survival estimates from diagnosis versus conditional survival.
  • Stratification by substage (IIIA, IIIB, IIIC).

Main Results:

  • Conditional survival significantly increases the estimated long-term survival probability.
  • For stage III melanoma, 5-year survival probability increased substantially for patients who had already survived 4 years.
  • Example: Stage IIIA survival increased from 72% to 95%.

Conclusions:

  • Routine use of conditional survival estimates is strongly recommended.
  • Conditional survival improves accuracy in patient counseling and survivorship program development.
  • Updated prognostic tools are essential for evolving patient care.